Validation of the important role and prognostic value of KIF14 in triple-negative breast cancer

验证KIF14在三阴性乳腺癌中的重要作用和预后价值

阅读:1

Abstract

BACKGROUND: Triple-negative breast cancer (TNBC) is an aggressive subtype with a poor prognosis and limited treatment options. Elevated Kinesin Family Member 14 (KIF14) expression in breast cancer (BC) is correlated with poor prognosis, but its role in TNBC remains unclear. METHODS: KIF14 expression was analyzed using TCGA, TIMER, and GEO databases, and its association with prognosis was assessed via Kaplan‒Meier plotter. Functional assays, including CCK-8, wound healing, and Transwell assays, were performed to evaluate KIF14's impact on TNBC cell proliferation, migration, and invasion. GO and KEGG analyses of transcriptome data were used to explore molecular mechanisms. The relationship between KIF14 expression and immune infiltration was assessed in the TIMER database. KIF14 expression in clinical samples was validated using qRT-PCR and immunohistochemistry, and its correlation with clinical features was examined. RESULTS: KIF14 was significantly upregulated in BC (P < 0.05), and elevated KIF14 expression was associated with poor prognosis. KIF14 knockdown reduced cell proliferation, migration, and invasion. Network analysis revealed its involvement in lipid metabolism, NF-κB, PI3K-AKT, and mTOR signaling pathways. Immune infiltration analysis showed a significant association between KIF14 and immune cell types. CONCLUSION: KIF14 promotes TNBC progression and serves as a potential diagnostic and prognostic biomarker for TNBC.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。